Chabiotech Co.,Ltd. Logo

Chabiotech Co.,Ltd.

Develops cell/gene therapies and provides CDMO and bio-banking services.

085660 | KO

Overview

Corporate Details

ISIN(s):
KR7085660009
LEI:
Country:
South Korea
Address:
서울특별시 강남구 도산대로 442 청담동 피엔폴루스 3층, 강남구

Description

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
투자판단관련주요경영사항(임상시험결과) (조기난소부전 환자에서의 CordSTEM-ST의 안전성 및 내약성을 평가하기 위한…
Korean 22.9 KB
2025-09-08 00:00
주식등의대량보유상황보고서(일반)
Korean 222.3 KB
2025-08-25 00:00
주식등의대량보유상황보고서(일반)
Korean 228.6 KB
2025-08-13 00:00
[기재정정]사업보고서 (2024.12)
Korean 4.7 MB
2025-08-13 00:00
반기보고서 (2025.06)
Korean 8.5 MB
2025-08-04 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.7 KB
2025-07-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-07-24 00:00
주식등의대량보유상황보고서(일반)
Korean 229.8 KB
2025-07-24 00:00
투자판단관련주요경영사항(임상시험결과) (알츠하이머병 환자에서 CB-AC-02 치료의 안전성과 잠재적 치료효과를 평가하기…
Korean 15.3 KB
2025-07-17 00:00
전환주식의전환가액조정 (상환전환우선주)
Korean 13.8 KB
2025-07-16 00:00
전환가액의조정
Korean 14.1 KB
2025-07-16 00:00
신주인수권행사가액의조정
Korean 14.3 KB
2025-06-23 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB
2025-06-23 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB
2025-06-23 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB

Automate Your Workflow. Get a real-time feed of all Chabiotech Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chabiotech Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chabiotech Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.